JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB144576

ZM306416 hydrochloride, VEGFR1/2 tyrosine kinase activity inhibitor

Be the first to review this product! Submit a review

|

(1 Publication)

MW 333.74 Da, Purity >98%. Potent and selective VEGFR1/2 inhibitor (IC50 values are 100 nM and 2 μM for KDR and Flt respectively). Shows antiproliferative effects in vivo. Orally active.
1 Images
Chemical Structure - ZM306416 hydrochloride, VEGFR1/2 tyrosine kinase activity inhibitor (AB144576)
  • Chemical Structure

Lab

Chemical Structure - ZM306416 hydrochloride, VEGFR1/2 tyrosine kinase activity inhibitor (AB144576)

2D chemical structure image of ab144576, ZM306416 hydrochloride, VEGFR1/2 tyrosine kinase activity inhibitor

Key facts

CAS number

690206-97-4

Purity

>98%

Molecular weight

333.74 Da

Molecular formula

C<sub>1</sub><sub>6</sub>H<sub>1</sub><sub>3</sub>ClFN<sub>3</sub>O<sub>2</sub>

PubChem

5329006

Nature

Synthetic

Solubility

Soluble in DMSO to 10 mM

Biochemical name

N-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine

Biological description

Potent and selective VEGFR1/2 inhibitor (IC50 values are 100 nM and 2 μM for KDR and Flt respectively). Shows antiproliferative effects in vivo. Orally active.

Canonical smiles

COC1=C(C=C2C(=C1)C(=NC=N2)NC3=C(C=C(C=C3)Cl)F)OC

InChi

InChI=1S/C16H13ClFN3O2/c1-22-14-6-10-13(7-15(14)23-2)19-8-20-16(10)21-12-4-3-9(17)5-11(12)18/h3-8H,1-2H3,(H,19,20,21)

InChiKey

YHUIUSRCUKUUQA-UHFFFAOYSA-N

IUPAC Name

N-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient
Storage information
The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The VEGF receptors—VEGF Receptor 1 (Flt-1) VEGF Receptor 2 (KDR/Flk-1) and VEGF Receptor 3 (Flt-4)—are tyrosine kinase receptors that mediate vascular endothelial growth factor (VEGF) signaling. These receptors vary in molecular mass with VEGF Receptor 1 being approximately 180 kDa VEGF Receptor 2 about 200 - 210 kDa and VEGF Receptor 3 around 195 - 200 kDa. They are expressed on the surface of various cells primarily vascular endothelial cells where they regulate different functions related to angiogenesis and lymphangiogenesis.
Biological function summary

These receptors play roles in modulating vascular permeability endothelial cell proliferation and blood vessel formation. They are part of complexes that include ligands such as various VEGF isoforms. VEGF Receptor 2 is the principal mediator of VEGF-induced endothelial cell responses. VEGF Receptor 1 serves as a decoy receptor to modulate the availability of VEGF for VEGF Receptor 2 whilst VEGF Receptor 3 mainly regulates lymphatic endothelial cell functions.

Pathways

These receptors are central to the VEGF signaling pathway which plays a role in angiogenesis and vasculogenesis. The pathway involves a cascade where VEGF binding leads to receptor dimerization and phosphorylation of intracellular domains activating downstream pathways like the MAPK and PI3K/Akt pathways. These receptors interact with various proteins including growth factors and other signaling molecules to ensure proper vascular function and adaptation.

Dysregulation of VEGF receptor signaling is implicated in cancer and retinal diseases. Overexpression or aberrant activation of VEGF Receptor 2 in particular is associated with tumor-induced angiogenesis allowing tumors to grow their own blood supply. In eye diseases like age-related macular degeneration improper VEGF signaling contributes to abnormal blood vessel formation. Other proteins such as neuropilins modulate these interactions serving as co-receptors to alter binding affinity and signaling output in disease contexts.

Product protocols

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

eLife 9: PubMed32366355

2020

Role of IL-4 in bone marrow driven dysregulated angiogenesis and age-related macular degeneration.

Applications

Unspecified application

Species

Unspecified reactive species

Takashi Baba,Dai Miyazaki,Kodai Inata,Ryu Uotani,Hitomi Miyake,Shin-Ichi Sasaki,Yumiko Shimizu,Yoshitsugu Inoue,Kazuomi Nakamura
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com